1h Free Analyst Time
Rheumatoid Arthritis - Pipeline Review, H2 2020Speak directly to the analyst to clarify any post sales queries you may have.
Summary
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Rheumatoid Arthritis - Pipeline Review, H2 2020, provides an overview of the Rheumatoid Arthritis (Immunology) pipeline landscape.
Rheumatoid arthritis (RA) is an autoimmune chronic disorder that eventually leads to destruction of bones causing deformities. Signs and symptoms of rheumatoid arthritis include tender, warm, swollen joints, fatigue, and fever and weight loss. Rheumatoid arthritis may be a result of genetic and certain specific environmental factors. Women are much more susceptible to develop RA. Treatment includes non-steroidal anti-inflammatory drugs, corticosteroid medications and immunosuppressants.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Rheumatoid Arthritis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Rheumatoid Arthritis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Rheumatoid Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 12, 2, 29, 43, 73, 10, 214, 59 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 5, 26 and 3 molecules, respectively.
Rheumatoid Arthritis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Rheumatoid Arthritis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rheumatoid Arthritis (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rheumatoid Arthritis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rheumatoid Arthritis (Immunology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rheumatoid Arthritis (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rheumatoid Arthritis (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionRheumatoid Arthritis - Overview
Rheumatoid Arthritis - Therapeutics Development
Rheumatoid Arthritis - Therapeutics Assessment
Rheumatoid Arthritis - Companies Involved in Therapeutics Development
Rheumatoid Arthritis - Drug Profiles
Rheumatoid Arthritis - Dormant Projects
Rheumatoid Arthritis - Discontinued Products
Rheumatoid Arthritis - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Rheumatoid Arthritis, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020 (Contd..1), H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Products under Development by Universities/Institutes, H2 2020 (Contd..1), H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Rheumatoid Arthritis - Pipeline by 3SBio Inc, H2 2020
- Rheumatoid Arthritis - Pipeline by 4D Pharma Plc, H2 2020
- Rheumatoid Arthritis - Pipeline by AB Science SA, H2 2020
- Rheumatoid Arthritis - Pipeline by AbbVie Inc, H2 2020
- Rheumatoid Arthritis - Dormant Projects, H2 2020
- Rheumatoid Arthritis - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Rheumatoid Arthritis, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio Inc
- 4D Pharma Plc
- AB Science SA
- AbbVie Inc
- AbClon Inc
- Abivax SA
- Ablynx NV
- ACEA Therapeutics Inc
- Acelerox LLC
- Aclaris Therapeutics Inc
- Adare Pharmaceuticals Inc
- Affilogic SAS
- Agency for Science, Technology and Research
- Ahead Therapeutics SL
- Aibios Co Ltd
- AimVion AS
- Akari Therapeutics Plc
- Alibion AG
- Allied-Bristol Life Sciences LLC
- Allosterix Ltd
- Alphamab Oncology
- Alpine Immune Sciences Inc
- Aluda Pharmaceuticals Inc
- Alvotech ehf
- Amgen Inc
- Amrif BV
- Anew Oncology Inc
- AnTolRx Inc
- Apaxen
- Apcegen Technologies Pvt Ltd
- Apitope International NV
- Applied Molecular Transport Inc
- Aprogen Inc
- Archigen Biotech Ltd
- arGentis Pharmaceuticals LLC
- Argenx SE
- Arrien Pharmaceuticals LLC
- Arthrogen BV
- Asahi Kasei Pharma Corp
- Astellas Pharma Inc
- AstraZeneca Plc
- Atlanthera
- Atlantic Bio Sci LLC
- Auransa Inc
- Aurigene Discovery Technologies Ltd
- Axsome Therapeutics Inc
- Axxam SpA
- Bayer AG
- Baylx Inc
- Beijing Eastern Biotech Co Ltd
- Beijing Hanmi Pharmaceutical Co Ltd
- Beijing VDJBio Co Ltd
- Bilix Co Ltd
- Bio-Cancer Treatment International Ltd
- Bio-Thera Solutions Ltd
- Biocad
- Biocon Ltd
- Biogen Inc
- Bioiberica SAU
- Biois Corp
- BioLingus AG
- BioLite Inc
- Biosion Inc
- Biotech Holdings
- BioXpress Therapeutics SA
- Biozeus Pharmaceutical SA
- Bristol-Myers Squibb Co
- BTB Pharma AB
- c-a-i-r Biosciences GmbH
- C4X Discovery Holdings Plc
- Cadila Healthcare Ltd
- Can-Fite BioPharma Ltd
- CannBioRex Pharmaceuticals Corp
- Carna Biosciences Inc
- CarthroniX Inc
- CEL-SCI Corp
- Cellics Therapeutics Inc
- Cellinbio Co Ltd
- CellTex Therapeutics Corp
- Celltrion Inc
- Cellworks Group Inc
- Cerecor Inc
- CHA Biotech Co Ltd
- CheckPoint Immunology Inc
- Chengdu Hyperway Pharmaceuticals
- Chipscreen Biosciences Ltd
- Chong Kun Dang Pharmaceutical Corp
- Citryll BV
- Clevexel Pharma SAS
- Clover Biopharmaceuticals
- Coherus BioSciences Inc
- Commence Bio Inc
- Compugen Ltd
- Cour Pharmaceuticals Development Co Inc
- Crossject SA
- CSL Ltd
- Curyx Bio Inc
- CV6 Therapeutics (Ni) Ltd
- Cyclacel Pharmaceuticals Inc
- Cytocom Inc
- Cyxone AB
- Daewoong Pharmaceutical Co Ltd
- DeMay Biotech
- Denali Therapeutics Inc
- Dendright Pty Ltd
- Diamyd Medical AB
- DiNonA Inc
- DM Bio Ltd
- DNX Biopharmaceuticals Inc
- Domainex Ltd
- Dr. Reddy's Laboratories Ltd
- Ducentis BioTherapeutics Ltd
- Dynavax Technologies Corp
- EHL Bio Co Ltd
- Enzene Biosciences Ltd
- Enzychem Lifesciences Corp
- Ergon Pharmaceuticals LLC
- Eternity Bioscience Inc
- Eton Pharmaceuticals Inc
- Evelo Biosciences Inc
- Fresenius Kabi SwissBioSim GmbH
- Fujifilm Kyowa Kirin Biologics Co Ltd
- Future Medicine Co Ltd
- Galapagos NV
- Gene Techno Science Co Ltd
- GeneFrontier Corp
- Genentech Inc
- Generium
- GeneScience Pharmaceuticals Co Ltd
- Genesen Co Ltd
- Genfit SA
- GenFleet Therapeutics (Shanghai) Inc
- Genor BioPharma Co Ltd
- Genosco Inc
- Genova Biotech Company Ltd
- Genrix (Shanghai) Biopharmaceutical Co Ltd
- Gismo Therapeutics Inc
- GlaxoSmithKline Plc
- GNT Biotech and Medicals Corp
- GNT Pharma Co Ltd
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- Guangzhou BeBetter Medicine Technology Co Ltd
- Han Wha Pharma Co Ltd
- Hana Pharm Co Ltd
- Hangzhou East China Pharmaceutical Group Co Ltd
- Hanlim Pharm Co Ltd
- Hebei Fitness Biotechnology Co Ltd
- HEC Pharm Co Ltd
- Hengenix Biotech Inc
- HitGen Inc
- HK inno.N Corp
- Hope Biosciences LLC
- HSRx Group
- Huabo Biopharm Co Ltd
- Hualan Biological Engineering Inc
- Humabs BioMed SA
- HuniLife Biotechnology Inc
- Hutchison MediPharma Ltd
- I-Mab Biopharma Co Ltd
- iBio Inc
- Ichnos Sciences Inc
- Idogen AB
- IL-2Rx Inc
- Iltoo Pharma
- ImCyse SA
- Immune Regulation Ltd
- Immungenetics AG
- Immunwork Inc
- Immutep Ltd
- Impetis Biosciences Ltd
- InflammatoRx inc
- Innate Pharma SA
- Innovent Biologics Inc
- Innovimmune Biotherapeutics Inc
- InSight Biopharmaceuticals Ltd
- Interprotein Corp
- Istesso Ltd
- Japan Tobacco Inc
- Jiangsu Carephar Pharmaceutical Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- JiangSu Qyuns Therapeutics Co Ltd
- Jinyu Bio-technology Co Ltd
- Johnson & Johnson
- Jubilant Therapeutics Inc
- Jyant Technologies Inc
- Kadmon Corp LLC
- Kang Stem Biotech Co Ltd
- KBP BioSciences Co Ltd
- Kemmx Corp
- Kezar Life Sciences Inc
- KIMS Pharmaceutical Co Ltd
- Kine Sciences
- Kiniksa Pharmaceuticals Ltd
- Korea United Pharm Inc
- Kymera Therapeutics LLC
- L2 Diagnostics LLC
- Landos Biopharma Inc
- Lead Pharma Holding BV
- Leukosight Inc
- LG Chem Ltd
- LipUm AB
- LISCure Biosciences Co Ltd
- Livzon MabPharm Inc
- Lupin Ltd
- Mabion SA
- Mabpharm Ltd
- Mabtech Ltd
- Mabwell Shanghai Bioscience Co Ltd
- Mabxience Holding SL
- Maruho Co Ltd
- MedAnnex Ltd
- MENTRIK Biotech LLC
- Merck & Co Inc
- Merck KGaA
- Mesoblast Ltd
- MetiMedi Pharmaceuticals Co Ltd
- MetrioPharm AG
- Microbiotix Inc
- Millennium Pharmaceuticals Inc
- Mirae Cell Bio Co Ltd
- Moogene Medi Inc
- Mycenax Biotech Inc
- MyeloRx LLC
- Nano Intelligent Biomedical Engineering Corp
- Nanode Therapeutics Inc
- Nascient Ltd
- Navigen Inc
- NeuClone Pty Ltd
- Neuracle Science Co Ltd
- Nichi-Iko Pharmaceutical Co Ltd
- North China Pharmaceutical Group New Drug Research and Development Co Ltd
- NovaCell Technology Inc
- NovalGen Ltd
- Novartis AG
- NuBioPharma LLC
- Numab Therapeutics AG
- Octagon Therapeutics Inc
- Omeros Corp
- Oncodesign SA
- OncoImmune Inc
- Oneness Biotech Co Ltd
- Oryn Therapeutics
- OSE Immunotherapeutics
- Pahan Therapeutics
- Paras Biopharmaceuticals Finland Oy
- Peptinov SAS
- Pfizer Inc
- Pharmapraxis
- Philogen SpA
- Promethera Biosciences SA
- ProNoxis AB
- Protab Ltd
- Protalex Inc
- Qu Biologics Inc
- R Pharm
- Radikal Therapeutics Inc
- Reata Pharmaceuticals Inc
- ReceptoPharm Inc
- RedHill Biopharma Ltd
- Regen BioPharma Inc
- Regenerative Arthritis & Bone Medicine Inc
- RemeGen Ltd
- Resverlogix Corp
- ReveraGen BioPharma Inc
- Rhizen Pharmaceuticals SA
- Ribomic Inc
- Richter Gedeon Nyrt
- Rigel Pharmaceuticals Inc
- Rophibio Inc
- ROS Therapeutics ApS
- Rottapharm Biotech Srl
- Saje Pharma LLC
- Sareum Holdings Plc
- SBI Biotech Co Ltd
- Sengenics International Pte Ltd
- Serene LLC
- Servatus Ltd
- Shandong Danhong Pharmaceutical Co Ltd
- Shanghai Biomabs Pharmaceuticals Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Pharmaceutical Group Co Ltd
- Siam Bioscience Co Ltd
- Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd
- Signablok Inc
- Simcere Pharmaceutical Group
- Singh Biotechnology LLC
- Sino Biopharmaceutical Ltd
- Sinocelltech Ltd
- SinoMab Bioscience Ltd
- siRNAgen Therapeutics Corp
- SomaLogic Inc
- Splash Pharmaceuticals Inc
- Suntec Medical (Taiwan) Inc
- Suzhou Connect Biopharmaceuticals Ltd
- Suzhou Ribo Life Sciences Co Ltd
- Suzhou Sinovent Pharmaceuticals Co Ltd
- SynAct Pharma AB
- Synermore Biologics Co Ltd
- Taiho Pharmaceutical Co Ltd
- Takeda Pharmaceutical Co Ltd
- Tasly Pharmaceutical Group Co Ltd
- TG Therapeutics Inc
- Tiziana Life Sciences Plc
- TLL Pharmaceutical LLC
- Toleranzia AB
- Tonix Pharmaceuticals Holding Corp
- TPCera Ltd
- Translational Biosciences
- Tumorend LLC
- Turgut Ilaclari AS
- Twoxar Inc
- United Biomedical Inc
- United BioPharma Inc
- Vaccinex Inc
- Vanworld Pharmaceutical (Rugao) Company Ltd
- Vascular Biogenics Ltd
- Viela Bio Inc
- Voronoi
- Wuhan Institute of Biological Products Co Ltd
- Wuxi Fuxin Pharmaceutical Research and Development Co Ltd
- X-Rx Inc
- Xalud Therapeutics Inc
- Xbrane Biopharma AB
- Xencor Inc
- XL-protein GmbH
- Y-Biologics Inc
- Yichang Humanwell Pharmaceutical Co Ltd
- Yuhan Corp
- Yungjin Pharm Co Ltd
- Zhejiang Hisun Pharmaceutical Co Ltd
- Zumutor Biologics Inc
- ZyVersa Therapeutics Inc
